An Overview



Conferences focusing on IgG4-related disease started in 2007 in Japan comprising a small group of Japanese researchers, as a meeting on type 1 autoimmune pancreatitis (AIP) and the various types of extrapancreatic organ involvement. It raised the field to a higher status, and the attendees resolved to conduct annual meetings for the study of “IgG4-related disease (IgG4-RD).” Subsequently, intensive studies on IgG4-RD have been carried out worldwide. In this chapter, we focused on the establishment of the concept of IgG4-RD, with special reference to IgG4 as a subclass of IgG, conditions causing abnormal elevations of IgG4 or associated with IgG4, clinical picture of IgG4-RD, and mechanisms underlying its development.


Thrombotic Thrombocytopenic Purpura Bullous Pemphigoid Epidermolysis Bullosa Autoimmune Pancreatitis Epidermolysis Bullosa Acquisita 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45(6):1538–46.PubMedCrossRefGoogle Scholar
  2. 2.
    Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. Am J Gastroenterol. 2003;98(12):2811–2.PubMedCrossRefGoogle Scholar
  3. 3.
    Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Ohara H, Nakazawa T, Sano H, et al. Systemic extrapancreatic lesions associated with autoimmune pancreatitis. Pancreas. 2005;31(3):232–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Hamano H, Arakura N, Muraki T, et al. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol. 2006;41(12):1197–205.PubMedCrossRefGoogle Scholar
  7. 7.
    Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64(10):3061–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Delves PJ, Martin SJ, Burton DR, Roitt IM. Roitt’s essential immunology. 12th ed. Hoboken: Wiley; 2011. ISBN 97814051966833.Google Scholar
  10. 10.
    Muraki T, Hamano H, Ochi Y, et al. Autoimmune pancreatitis and complement activation system. Pancreas. 2006;32(1):16–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78(10):1016–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Kawano M, Saeki T, Nakashima H, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15(5):615–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Cornell LD, Chicano SL, Deshpande V, et al. Pseudotumors due to IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatocentric disease. Am J Surg Pathol. 2007;31(10):1586–97.PubMedCrossRefGoogle Scholar
  14. 14.
    Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011 Jul;22(7):1343–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamaguchi Y, Kanetsuna Y, Honda K, et al. Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol. 2011;43(4):536–49.PubMedCrossRefGoogle Scholar
  16. 16.
    van der Neut KM, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554–7.CrossRefGoogle Scholar
  17. 17.
    Rispens T, Ooievaar-De Heer P, Vermeulen E, et al. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol. 2009;182(7):4275–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Kawa S, Kitahara K, Hamano H, et al. A novel immunoglobulin-immunoglobulin interaction in autoimmunity. PLoS One. 2008;3(2):e1637.PubMedCrossRefGoogle Scholar
  19. 19.
    Shakib F, Stanworth DR, Drew R, et al. A quantitative study of the distribution of IgG sub-classes in a group of normal human sera. J Immunol Methods. 1975;8(1–2):17–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Fernandez-Flores A. The role of IgG4 in cutaneous pathology. Rom J Morphol Embryol. 2012;53(2):221–31.PubMedGoogle Scholar
  21. 21.
    Manso EC, Morato-Castro FF, Yee CJ, et al. Honeybee venom specific IgG subclass antibodies in Brazilian beekeepers and in patients allergic to bee stings. J Investig Allergol Clin Immunol. 1998;8(1):46–51.PubMedGoogle Scholar
  22. 22.
    Ottesen EA, Skvaril F, Tripathy SP, et al. Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol. 1985;134(4):2707–12.PubMedGoogle Scholar
  23. 23.
    Iskander R, Das PK, Aalberse RC. IgG4 antibodies in Egyptian patients with schistosomiasis. Int Arch Allergy Appl Immunol. 1981;66(2):200–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012;135(Pt 4):1081–101.PubMedCrossRefGoogle Scholar
  25. 25.
    Beck Jr LH, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 2010;77(9):765–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Ferrari S, Mudde GC, Rieger M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009;7(10):1703–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Okazaki K, Chiba T. Autoimmune related pancreatitis. Gut. 2002;51(1):1–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Kawa S, Hamano H. Clinical features of autoimmune pancreatitis. J Gastroenterol. 2007;42 Suppl 18:9–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Kamisawa T, Takuma K, Egawa N, et al. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol. 2010;7(7):401–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol. 2009;22(4):589–99.PubMedCrossRefGoogle Scholar
  33. 33.
    Matsubayashi H, Uesaka K, Kanemoto H, et al. Soluble IL-2 receptor, a new marker for autoimmune pancreatitis. Pancreas. 2012;41(3):493–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Masaki Y, Kurose N, Yamamoto M, et al. Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease. Int J Rheumatol. 2012;2012:580814.PubMedGoogle Scholar
  35. 35.
    Yamamoto M, Tabeya T, Naishiro Y, et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol. 2011;22(3):419–25.PubMedCrossRefGoogle Scholar
  36. 36.
    Strehl JD, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol. 2011;64(3):237–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Houghton DC, Troxell ML. An abundance of IgG4+ plasma cells is not specific for IgG4-related tubulointerstitial nephritis. Mod Pathol. 2011;24(11):1480–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Watanabe T, Yamashita K, Fujikawa S, et al. Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis. Arthritis Rheum. 2012;64(3):914–24.PubMedCrossRefGoogle Scholar
  39. 39.
    Watanabe T, Yamashita K, Sakurai T, et al. Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. J Gastroenterol. 2013;48(2):247–53.PubMedCrossRefGoogle Scholar
  40. 40.
    Kiyama K, Kawabata D, Hosono Y, et al. Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res Ther. 2012;14(2):R86.PubMedCrossRefGoogle Scholar
  41. 41.
    Okazaki K. Clinical relevance of autoimmune-related pancreatitis. Best Pract Res Clin Gastroenterol. 2002;16(3):365–78.PubMedCrossRefGoogle Scholar
  42. 42.
    Guarneri F, Guarneri C, Benvenga S. Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry? J Cell Mol Med. 2005;9(3):741–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Kawa S, Ota M, Yoshizawa K, et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology. 2002;122(5):1264–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Freitag TL, Cham C, Sung HH, et al. Human risk allele HLA-DRB1*0405 predisposes class II transgenic Ab0 NOD mice to autoimmune pancreatitis. Gastroenterology. 2010;139(1):281–91.PubMedCrossRefGoogle Scholar
  45. 45.
    Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum. 2012;64(1):254–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Maehara T, Moriyama M, Nakashima H, et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease. Ann Rheum Dis. 2012;71(12):2011–20.PubMedCrossRefGoogle Scholar
  47. 47.
    Yamamoto M, Takahashi H, Tabeya T, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol. 2011;22(3):414–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Center for Health, Safety, and Environmental ManagementShinshu UniversityMatsumoto CityJapan
  2. 2.Division of RheumatologyKanazawa University HospitalKanazawaJapan

Personalised recommendations